RxDoctor Payments Data

Yoram Moyal, MD

Internal Medicine · Mayfield Village, OHNPI 1194730580

Payments from drug & device makers

$10,077in general payments, 2019–2025

Across 581 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Amgen$1K
  • Lilly USA, LLC$504
  • AstraZeneca$439
  • Novo Nordisk$378
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$10,032100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,077 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$198,262
Medicare patients
434
Services billed
3,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide105$109,056
OzempicSemaglutide64$55,716
JardianceEmpagliflozin41$46,237
EliquisApixaban53$44,764
Repatha SureclickEvolocumab46$42,117
FarxigaDapagliflozin Propanediol24$19,716
Breo ElliptaFluticasone/Vilanterol20$11,175
TrulicityDulaglutide12$10,953
ViberziEluxadoline12$9,441
Aimovig AutoinjectorErenumab-Aooe12$8,809
Rosuvastatin Calcium475$4,176
Mirtazapine95$3,978
Atorvastatin Calcium430$3,607
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm18$2,961
Gabapentin180$2,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$504$120,009117 claims
Novo NordiskOzempic$378$55,71664 claims
Boehringer IngelheimJardiance$31$46,23741 claims
PfizerEliquis, Paxlovid$1,191$46,13168 claims
AstraZenecaFarxiga$439$19,71624 claims
AbbVieViberzi, Synthroid$2,420$12,04256 claims
GSKBreo Ellipta$331$11,17520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Mayfield Village

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →